Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders.

Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.

[1]  G. Prud’homme,et al.  Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. , 2011, Experimental and molecular pathology.

[2]  T. Nemoto,et al.  Successful treatment of desmoid tumor of the chest wall with tranilast: a case report , 2010, Journal of medical case reports.

[3]  Y. Glinka,et al.  Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist , 2010, PloS one.

[4]  Satoshi Kobayashi,et al.  Tranilast modulates fibrosis, epithelial‐mesenchymal transition and peritubular capillary injury in unilateral ureteral obstruction rats , 2010, Pathology.

[5]  K. Izumi,et al.  Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer. , 2010, Anticancer research.

[6]  G. Prud’homme,et al.  Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer , 2010, Anti-cancer drugs.

[7]  A. Naiki‐Ito,et al.  Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro , 2010, The Prostate.

[8]  Russell S. Thomas,et al.  Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. , 2010, Molecular endocrinology.

[9]  K. Miyazaki,et al.  Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. , 2009, International journal of oncology.

[10]  S. Safe,et al.  The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. , 2009, Endocrine-related cancer.

[11]  E. Keller,et al.  Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1‐associated osteoblastic changes , 2009, The Prostate.

[12]  G. Prud’homme,et al.  Tranilast inhibits the growth and metastasis of mammary carcinoma , 2009, Anti-cancer drugs.

[13]  Mutsuo Takahashi,et al.  Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. , 2009, The Tohoku journal of experimental medicine.

[14]  N. Kerkvliet.  AHR-mediated immunomodulation: the role of altered gene transcription. , 2009, Biochemical pharmacology.

[15]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.

[16]  T. Onozuka,et al.  Vulval syringoma successfully treated with tranilast , 2005, The British journal of dermatology.

[17]  清水 俊行.  Suppression of matrix metalloproteinase production in nasal fibroblasts by tranilast, an antiallergic agent, in vitro , 2005 .

[18]  M. Yashiro,et al.  Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. , 2003, Anticancer research.

[19]  S. Kawashiri,et al.  Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. , 2003, Oral oncology.

[20]  T. Nikaido,et al.  Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  E. Uchida,et al.  Anti-tumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer. , 2002, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[22]  J. Dichgans,et al.  N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) inhibits transforming growth factor‐β release and reduces migration and invasiveness of human malignant glioma cells , 2001, International journal of cancer.

[23]  H. Miyata,et al.  Tranilast : A new application in the cardiovascular field as an antiproliferative drug , 1998 .

[24]  L. Nie,et al.  Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel. , 1997, Cell calcium.

[25]  Y. Chung,et al.  Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. , 1997, Anticancer research.

[26]  茂木 定之.  Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast , 1997 .

[27]  N. Katoh,et al.  Solitary Mastocytoma Treated with Tranilast , 1996, The Journal of dermatology.

[28]  T. Nishikawa,et al.  Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. , 1994, Journal of biochemistry.

[29]  K. Ichikawa,et al.  Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. , 1993, Japanese Journal of Pharmacology.

[30]  K. Yoshikawa,et al.  Clinical Evaluation of Tranilast for Keloid and Hypertrophic Scar , 1992 .

[31]  M. Nakazawa,et al.  Study of the mechanism of inhibitory action of tranilast on chemical mediator release. , 1988, Japanese journal of pharmacology.

[32]  M. Isaji,et al.  Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5') in granulation tissue. , 1987, Biochemical pharmacology.

[33]  A. Koda,et al.  The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid. , 1985, International archives of allergy and applied immunology.

[34]  H. Azuma,et al.  PHARMACOLOGICAL PROPERTIES OF N‐(3′,4′‐DIMETHOXYCINNAMOYL) ANTHRANILIC ACID (N‐5′), A NEW ANTI‐ATOPIC AGENT , 1976, British journal of pharmacology.

[35]  Y. Yanagihara,et al.  Inhibition of hypersensitivity reactions by a new drug, N(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'). , 1976, The Journal of allergy and clinical immunology.